Treatments

How Is Non-Hodgkin’s Lymphoma Treated?

This content has been reviewed and approved by
James O. Armitage, MD
The Joe Shapiro Professor of Internal Medicine
Section of Oncology/Hematology
University of Nebraska Medical Center

The treatment for a particular patient with non-Hodgkin's lymphoma will depend on many characteristics. These include the following:

  • The specific type of lymphoma
  • Your age, overall health, and medical history
  • The extent of disease and your IPI score
  • Your tolerance of specific medications
  • Your opinion or preference. It is always important to remember who works for whom in the doctor-patient relationship. The physician's responsibility is to explain the situation as clearly as possible and make his or her best recommendation, but in the end to follow your preference.

    The actual treatments employed vary widely. There are some patients with less aggressive lymphomas who don't have any symptoms and who need only observation. When this is the treatment decision, it is very important that patients be watched closely because any lymphoma can progress and develop dangerous symptoms.

When initial treatment is determined, there are only a few choices to treat any cancer. These include removing the cancer (surgery), killing the cancer with high energy radiation (radiation therapy), or the use of chemical treatments. The latter might include traditional anticancer drugs, new anticancer drugs, and antibodies that might or might not also deliver radiation.

For most patients, because of the widespread nature of lymphomas, the initial treatment will involve chemical treatments. For younger patients with very poor prognosis lymphomas or those in whom the lymphoma has recurred after the initial treatment, bone marrow transplantation using one's own cells (autologous transplantation) or cells from another person (allogeneic transplantation) might be the best treatment.

 

 

This content was last modified on August 15, 2007 .

Latest Non-Hodgkin's Lymphoma News

  • May 14, 2008
    Smoking and Heavy Alcohol Consumption Reduce Survival in Non-Hodgkin's Lymphoma
    Patients diagnosed with non-Hodgkin’s lymphoma (NHL) who smoke tobacco products and/or drink large quantities of alcohol have a reduced chance of optimal survival. These results were recently published in the International Journal of Cancer.
  • May 8, 2008
    Worse Prognosis for “Bulky” Disease Diffuse Large B-Cell Lymphoma
    Young patients with diffuse large-B-cell lymphoma (DLBCL) with cancerous masses that are 10.0 centimeters or greater in diameter are considered to have “bulky” disease and have a worse prognosis than those with smaller masses. These findings were published in Lancet Oncology.
  • May 5, 2008
    Treanda® Included in NCCN Guidelines for CLL and NHL
    The chemotherapy agent Treanda® (bendamustine) has been added to the treatment guidelines of the National Comprehensive Cancer Network (NCCN) as an accepted treatment option for chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).
Select news items provided by Reuters Health
More Cancer News

Privacy Policy reviewed by TRUSTe

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health
Information:
verify here.

Secure transactions for this website use a thawte certificate to ensure secure transmission of your information.